Stock Analysis
GSK plc (GSK) Stock Analysis
GSK plc (GSK) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
GSK plc (GSK) currently has an AIQ Score of 62/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk is the weakest current factor at 46/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
GSK at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $49.51 |
| AIQ Score | 62/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Sell |
| Market Cap | $101.5B |
| P/E Ratio (TTM) | 15.6 |
| Forward P/E | — |
| EPS (quarter ended 2026-06-30) | $0.22 |
| Revenue (quarter ended 2026-06-30) | $8.41B |
| Dividend Yield (TTM) | 3.63% |
| Beta | 0.3 |
| Volume | 4.77M |
| 52-week range | $45.50-$61.70 |
| RSI 14 | 60.32 |
| 50-Day SMA | $49.48 |
| 200-Day SMA | $52.35 |
| Analyst Price Target | $60.00 |
| Next Earnings | Feb 3, 2027 |
GSKGSK plc
Healthcare / Drug Manufacturers - General
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum51
- Value67
- Quality73
- Risk resilience46
- Sentiment—
GSK Stock Analysis Summary
GSK plc (GSK) currently has an AIQ Score of 62/100, indicating a neutral setup. Quality is the strongest factor at 73/100. Risk resilience is the weakest current factor at 46/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, GSK has AIQ Score of 62/100 with Quality base of 73/100 and fading Risk resilience at 46/100. Wait for component alignment before adding exposure.
Quality (73/100) leads while Risk resilience (46/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 1.71% stock move · GSK classified in Drug Manufacturers - General.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is GSK Bullish or Bearish Right Now?
GSK currently has a neutral overall setup. Quality is the strongest factor at 73/100, while Risk Resilience is weakest at 46/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 73/100.
- - Analyst target implies +21.19% upside from the latest quote.
- - Price is -7.01% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (22 vs 15).
Current Consensus
GSK's Technical Analysis Consensus is currently Sell, with 15 buy, 8 neutral, and 22 sell votes. GSK's 14-day RSI is 60.32, which places the stock in a constructive momentum range. GSK's beta is 0.3, indicating lower market sensitivity than the broad market.
What Changed in GSK?
The largest recent change in GSK is Momentum moving down by 22.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the GSK Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
GSK Decision Framework
Public evidence layers, setup checks, and risk context for GSK plc.
GSK plc (GSK) Stock Analysis
GSK plc has an AIQ Score of 62/100 in a Neutral regime. Quality is strongest at 73/100. Beta is 0.28, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | GSK is in a Neutral AIQ regime with score 62/100. |
| Signal Conflict | The primary conflict is that quality leads at 73/100 while risk lags at 46/100. |
| Factor Evidence | Momentum 51/100 · Value 67/100 · Quality 73/100 · Risk 46/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 73/100.
Momentum is 51/100 and RSI (14) is 60.3.
GSK is in a Neutral regime at 62/100.
Risk factor is 46/100 with beta 0.28 and annual volatility 25.98%.
Current conflict: quality leads at 73/100 while risk lags at 46/100.
GSK Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
GSK Fundamentals
GSK valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
GSK Technical Analysis
GSK technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
GSK Stock Catalysts
Track GSK earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
GSK Dividend Analysis
GSK dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
GSK Financial Data
GSK revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
GSK Risk Analysis
GSK volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
GSK Stock News
GSK stock news, market tone, recent headlines, and catalyst context.
GSK vs Large Cap Pharma Peers
Current peer cohort: GSK · HLN · INCY · JNJ · LLY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| GSK Current stock | 62/100 | 67/100 | 51/100 | 46/100 | 0.2 | 25.98% | Current |
| HLN Haleon | 49/100 | 56/100 | 32/100 | 37/100 | -0.2 | 27.48% | GSK vs HLN |
| INCY Incyte | 68/100 | 52/100 | 57/100 | 71/100 | 0.82 | 33.70% | GSK vs INCY |
| JNJ Johnson & Johnson | 60/100 | 38/100 | 79/100 | 47/100 | 1.8 | 20.74% | GSK vs JNJ |
| LLY Eli Lilly | 61/100 | 26/100 | 95/100 | 46/100 | 1.54 | 35.59% | GSK vs LLY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Oct 29, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts3 recent quarterly periods are available for review.
Checked Oct 31, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching GSK
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for GSK
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
GSK Stock FAQ
What is GSK stock price today?
GSK plc's current stock price is $49.51. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is GSK bullish or bearish right now?
GSK's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is GSK's market cap?
GSK's market cap is $101.5B based on the latest completed market-close snapshot from Oct 30, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is GSK's current P/E ratio?
GSK's current P/E ratio is 15.6 based on the latest completed market-close snapshot from Oct 30, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is GSK's RSI?
GSK's 14-day RSI is 60.32 based on the latest completed market-close snapshot from Oct 30, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is GSK above its 50-day and 200-day moving averages?
GSK is -1.62% from its 50-day SMA and -7.01% from its 200-day SMA based on the latest completed market-close snapshot from Oct 30, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is GSK's next earnings date?
GSK's next earnings date is currently listed as Feb 3, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does GSK pay a dividend?
GSK's dividend yield is 3.63% based on the latest completed market-close snapshot from Oct 30, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.